Individuals Stopping Anti-Obesity Jabs Regain Weight Far More Rapidly Compared to People Using Diet and Exercise

New research suggests that patients who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt traditional diet and exercise plans.

Findings released in a major medical journal demonstrates that while overweight people frequently drop about a fifth of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.

"Users using such drugs need to be informed of the potential of rapid rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.

Such speed of recovery means a return to starting mass in about a year and a half.

Comparing Therapies

The research, which reviewed 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.

Scientists emphasize that individuals who lose weight through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.

Understanding the Quick Rebound

Experts propose the mechanism of the drugs accounts for the heightened rebound.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this hormone supplement results in hunger is no longer kept in check, making binge eating a significant risk."

An Ongoing Condition?

Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.

Many experts say that, given the significant potential of weight regain, the treatment is often ongoing.

This view is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," similar to managing conditions like hypertension.

User Accounts

People who have come off the jabs describe a sudden return of cravings.

"I experienced a switch activating and I was suddenly extremely hungry," recalled one woman.

This challenge is compounded if patients have not developed permanent lifestyle or habit changes during treatment.

Growing Use

Survey data indicate that millions of adults in the UK have used these injections in the past year, with interest continuing to grow.

• Adoption is higher among females compared to men.
• The middle-aged age group shows the greatest level of interest.
• A large proportion obtain the drugs through private prescriptions rather than public health services.

In conclusion, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on integrated behavioural support.